If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Business Update

10 May 2012 07:00

RNS Number : 0316D
ViaLogy PLC
10 May 2012
 



VIALOGY ACHIEVES MAJOR COMMERCIAL MILESTONES

 

Pasadena, CA, May 10, 2012. ViaLogy PLC (LSE/AIM: VIY). In a business update issued today ViaLogy said the last two months marked a major progress milestone in the company's development. New commercial contracts have been signed with three of the largest global Exploration and Production (E&P) firms, including two supermajors. All are focused on putting the company's technology, QuantumRD, to operational use in some of the world's most important development fields, and aiming to improve significantly on industry-standard techniques now in use. The named contracts include the Oil and Natural Gas Corporation of India (ONGC), and Chevron.

The three areas covered by the contracts vary widely in their features; they are geographically distant from one another, and of distinct formation types - sandstones, carbonates, and non-conventional shale. Each has challenged best-of-practice conventional seismic analysis techniques. One is offshore in deepwater, one in an already heavily exploited onshore carbonate formation where secondary development and horizontal drilling are key factors, and one is a new development section of one of the world's largest and, until now, most productive fields. This variety of QuantumRD's applications emphasizes the broad utility of the signal processing technology in addressing E&P challenges worldwide.

The contracts also mark the company's move into the global geophysical services marketplace, with the objective that success in work underway will lead to widespread use of QuantumRD. The company is at work on winning other large operators and supermajors as clients, for some of whom difficult pilot projects have been completed. ViaLogy also continues to work with some of its smaller clients.

QuantumRD brings quantum physics and quantum mathematics to the challenge of processing seismic data to more effectively locate oil and gas, and to characterize reservoirs. More importantly, QuantumRD brings an important value proposition to the upstream E&P sector - simply put, to achieve cost savings associated with fewer or more efficient wells drilled per barrel of oil extracted.

CEO Robert Dean said, "Over the last few years, we've devoted every resource to breaking into the supermajor market. We adopted a strategy and are achieving our goals in deliberate fashion -identifying and developing the right clients, winning projects that subject the technology to rigorous technical scrutiny, and demonstrating its global reach. This is not an event; it's a process. We believe we are well on our way. From an initial successful project in south central Texas, and also counting some disappointments, we're now working in the world's most challenging fields - such as offshore India -- and with the world's most important companies. Our current contracts are sizable; larger ones should follow. The technology is under sustained technical scrutiny by the finest in the industry; we ourselves have more development work to do. But we believe ViaLogy has passed the tipping point."

 

For further information contact: 

ViaLogy

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy/Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Katie Ratner, Corporate Broking +44 (0) 20-7107-8000

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery. ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDGGDUGUGBGDC
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.